Brefeldin A

For research use only.

Catalog No.S7046

24 publications

Brefeldin A  Chemical Structure

CAS No. 20350-15-6

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Brefeldin A has been cited by 24 publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 MkS2SpVv[3Srb36gRZN{[Xl? MWSyJO69VQ>? NFj5[5AyKGh? NHPF[mdqdmirYnn0d{B1cGViTD3EU3BCKCh{MNMg{txOMS2rbnT1Z4VlKHS{YX7zbYVvfCCHUluxM|IheGixc4Doc5J6dGG2aX;uxsA> NHXCS|EzPjN4M{G5NS=>
C2C12 MkXrSpVv[3Srb36gRZN{[Xl? NEPiTpgyyqEQvHevcYw> NGDpeZUyyqCq MYPhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz NFTHZpgzPjJ7MUK3PS=>
MEFs WT NGPMW4NHfW6ldHnvckBCe3OjeR?= MofCOeKh|ryP Ml7VNlAhdWmw NEDG[lNk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU NXzMUo1HOjZzOU[wNlM>
MEFs VAMP7 KO NUS1OId6TnWwY4Tpc44hSXO|YYm= NVP1OIVIPcLizszN NVK4[JRoOjBibXnu MVjjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT NHXqO4szPjF7NkCyNy=>
SMCs MkDXSpVv[3Srb36gRZN{[Xl? NHHJXmIyOMLiwsXnM41t MWmwMVEzKGh? MYnEUXNQ Mn\wd4hwf3NiYTD0doVv\CC2b4fhdoR{KGFiaHnnbIVzKGOxbnPlcpRz[XSrb36gc4YhfGinIFXSM3NTKG6ndIfvdoshcW5idHjlJJBmemmwdXPs[YFzKGG{ZXJCpC=> MVKyOlE4OjB6MB?=
SMCs M1H0cWZ2dmO2aX;uJGF{e2G7 NFzkUIoyOMLiwsXnM41t NHrlU5MxNTF{IHi= MnvNSG1UVw>? MWHjZZV{\XNiYTD0doFve2mnboSgR4EzM8LicnXs[YF{\SCocn;tJJRp\SCHUj;TVuKh NWP3RXljOjZzN{KwPFA>
HEMC-1 NGLyO5lHfW6ldHnvckBCe3OjeR?= M4SySFAvOcLiwsXnM41t NFvW[5QzPMLiaB?= MorSZ4F2e2W|IHGgbIlocGW{IHnubIljcXSxcomg[YZn\WO2IH;uJIV5d2O7dH;zbZMhfGijbjDuc4Nw\GG8b3zl NUTI[|lkOjV7N{K3OVk>
HUVEC MnXjSpVv[3Srb36gRZN{[Xl? Mn7HNVDDqM7:TR?= MUixxsBp M2rvPGROW09? NGnveGZi[m:uaYPo[ZMhcHmyb4jpZU1qdmS3Y3XkJJJmdGWjc3Wgc4YhSVSSIH\yc40h[XCrY3HsJIFv\CCkYYPvcIF1\XKjbDDzeZJn[WOncx?= NIL1VnMzPTl3Nkm4PC=>
HUVEC MV3GeY5kfGmxbjDBd5NigQ>? M3y3dFExyqEQvF2= NV;nXYY{OcLiaB?= NG\KbmdFVVOR M1nwe4lv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= MVOyOVk2Pjl6OB?=
Caco-2 NGT0b3dHfW6ldHnvckBCe3OjeR?= M3nwVFIvPSEQvF2= NUPNb5dROzBibXnu M4LzS4F1fGWwdXH0[ZMhfGinIGTHSk3PujFvbXXkbYF1\WRiaX7jdoVie2ViaX6gV2VTXCCodX7jeIlwdg>? MVqyOVk2PDl|MR?=
NRK NVzJ[mF3TnWwY4Tpc44hSXO|YYm= MoPCNlAx6oDHbnevcYw> NUfOdHZVPOLChXi= MlL5SG1UVw>? MlzkdoV{[3WnczDtbZRwfGmlIIDyc4dz\XO|aX;u NGjjT|MzPTl2OEW4Oi=>
HeLa MoHESpVv[3Srb36gRZN{[Xl? NIXGbJIzODEkgJXu[{9udA>? M{fEZVMhcA>? M1;PNmROW09? NI\T[3dqdmS3Y3XzJJRp\SCjcoTp[olkcWGuIHLy[YFsNXWyIH;mJJRp\SCJb3znbUBkd22ybHX4 NYnpdZEyOjV7NEi1PFY>
COS M2\UfWZ2dmO2aX;uJGF{e2G7 M13W[lEh|rypL33s NXv1cVBvOyCq MWLjc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> MXuyOVkyPTlyMB?=
DF1  M2ThZ2Z2dmO2aX;uJGF{e2G7 MmfKNeKh|ryPwrC= NXnrPIo2PDhiaB?= MnXiSG1UVw>? NVK0eHFm\Gm|cHXyd4V{yqC2aHWg[Zhw\2Wwb4XzJGNUT2GuTlHjWFIheHKxdHXpci=> NVfVcZJWOjV6MEewOVQ>
nHDFs  MUjGeY5kfGmxbjDBd5NigQ>? MlO5NeKh|ryPwrC= NFXUV|QzyqCq M3TFWJBz\X[nboTzJJRp\SCjc4PlcYJtgSCxZjDjfZRwe2:uaXOgZ49ifCCycn;0[YlveyCxboTvJGdwdGerIH3lcYJz[W6ncx?= MWGyOVc4OjZzNh?=
FRT  MYLGeY5kfGmxbjDBd5NigQ>? MWK1JO69\y:vbB?= NFLKeHQzyqCq MoG4Zoxw[2u|IITyZYZncWOtaX7nJJRpem:3Z3igeIhmKEexbHfpJINwdXCuZYigZpkhcW6qaXLpeIlv\yCHUj30c{1Id2ypaTD0doFve3CxcoS= MnfINlU4PjdzMUW=
FRT  M1rHZ2Z2dmO2aX;uJGF{e2G7 NYDF[5pWPSEQvHevcYw> NGK5d4YzyqCq NGHJToNxemW4ZX70d{B1cGViaX7jdoVie2ViaX6gZ4xm[X[nZDFOtUB{fWK3bnn0d{B4cGWwIGvOZUteccLid3HzJJJm\HWlZXS= MUGyOVc3PzFzNR?=
HepG2  NFG3NXNHfW6ldHnvckBCe3OjeR?= MkLxNgKBkcL3TdMg MnLrNlQhcA>? NGDrTZNFVVOR NFHGSFll\WO{ZXHz[ZMhfGinIHzleoVtKG:oIGDYVkBuWk6D NH3iT5UzPTZzNkW5Oy=>
SMCs NGrHSYpHfW6ldHnvckBCe3OjeR?= M1PPOlHPxGdxbVy= MWqzJIg> MnzpZYNkfW23bHH0[ZMhS06SWUKgdJJwfGWrbjDpckB1cGViRWKgZ49ueGG{dH3lcpQh[W6mIH7vJIxwdmencjDjc{1td2OjbHn6[YQhf2m2aDD0bIUhT2:uZ3mgcYFzc2W{wrC= MYCyOVU5QTR{NR?=
OB-6 MmjGRZBweHSxc3nzJGF{e2G7 NH[xclIzNjgEoN88US=> M4HPR|Q5KGh? M1nwdIlv\HWlZYOgZZBweHSxc3nz NXLBb21ROjV3M{K0PFA>
iPSC-CMs  NV[0eW5uTnWwY4Tpc44hSXO|YYm= NU\T[os2PTByIH7nM41t MWe0PEBp NH30VJpqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| M3PtSVI2PDh6Nk[2
SP-Nluc NEi1SpBHfW6ldHnvckBCe3OjeR?= M1\TUFUhdWdxbVy= NGDPem43KGh? NYXOZZRwTE2VT9Mg MXPjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl M3z1eFI2Ozl{OUm4
PEXEL-Nluc NV;F[I1{TnWwY4Tpc44hSXO|YYm= NYTRXXVjPSCvZz;tUC=> MUi2JIg> NVzjZ5RWTE2VT9Mg NWXCOIZF[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? MUOyOVM6Ojl7OB?=
H1299 MkXxSpVv[3Srb36gRZN{[Xl? MkLnNVAh|rypL33s MWmyOEBp MUTpcoR2[2W|IHH1eI9xcGGpedMg Ml7RNlU{QDh7N{C=
MDA-MB-231 MnLHR4VtdCCYaXHibYxqfHliQYPzZZk> NU[1[XhHOOLCk{WwJO69\y:vTB?= MWK0PEBp MmHZSWM2OMLiPTCwMlAyPiEEtXevcWw> MnHoNlU{PTZ3Nke=
MDA-MB-231 MXnBdI9xfG:|aYOgRZN{[Xl? NF7rdFUxNjFizsznM41N NVm5TZNxPCCq MUXpcoR2[2W|IHHwc5B1d3Orcx?= MnfiNlU{PTZ3Nke=
MDA-MB-231 M33QW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf1PGpJOC5yMT:wMlA2KM7:Zz;tUC=> MV6yOEBp Moe5bY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDzeYIuTzFiY3XscEBl\WK{aYO= Mn;mNlU{PTZ3Nke=
MDA-MB-231 MX7BdI9xfG:|aYOgRZN{[Xl? M1rMXlAvODYkgKOxJO69\y:vTB?= MYmyOEBp M4PWRYlv\HWlZYOgVGFTWCBqcH;sfUBCTFBvcnnic5NmKHCxbInt[ZJie2VvMTmgZ4xm[X[jZ3W= MkLzNlU{PTZ3Nke=
MDA-MB-231 MYLGeY5kfGmxbjDBd5NigQ>? NHfB[lYx6oDVNUCg{txoN22O M17D[|I1KGh? Ml35bY5pcWKrdIOgeIhmKG[xcn3heIlwdiCxZjCzSEBidmRiMlSgZ49td26rZYO= MlP0NlU{PTZ3Nke=
A172 MmPSSpVv[3Srb36gRZN{[Xl? MlzTNVDDqM7:Zz;tcC=> MmjZOOKhcA>? M3;kdGROW00EoB?= NE\qSVBz\XO3bITzJIlvKHSqZTDy[ZRzd2e{YXTlJJRz[W6|cH;yeEBw\iCobIXvdoV{[2WwdDDndoFvfWyncx?= M2\LflI2OjN7NUC3
KMS-6 NVHReXNJTnWwY4Tpc44hSXO|YYm= Ml;3NeKh|ryPwrC= M324VlI1KGh? MVLlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? NFPaSoIzPTJ{OUGyOi=>
MEC NUDZ[3VvTnWwY4Tpc44hSXO|YYm= M2PuT|Eh|ryP NGHhcnIyNjViaB?= MofxZ4F2e2W|IHGg[JJidWG2aXOg[IVkemWjc3WgbY4hfGinIIP1doZi[2ViVlXHSnIz MVGyOVIzQDhzNR?=
HEK293/hERG NFjuZ|NHfW6ldHnvckBCe3OjeR?= MnPaNVDDqM7:TR?= Moq3NeKhcA>? M2L1cpJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi MlriNlUzOTh2Nkm=
RBE4 MXPBdI9xfG:|aYOgRZN{[Xl? NG\wb2IzyqEQvF2= NGftWHY{6oDVMkVCpIg> NHvkfY1qdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 NV3FV5ZUOjVzMkiwNlU>
RBE4 NIXUUlNHfW6ldHnvckBCe3OjeR?= M2PaNFLDqM7:TR?= MWqz5qCUOjUEoHi= NHjMTG1qdmO{ZXHz[ZMhfGinIGjCVFEheHKxdHXpckBt\X[nbIOgZYZ1\XJiMzDhcoQhPsLiaDDv[kB1emWjdH3lcpQ> MXyyOVEzQDB{NR?=
RBE4 MnHGSpVv[3Srb36gRZN{[Xl? M{fFdVLDqM7:TR?= M1LkUlPjiJN{NNMgbC=> NHrSc2tqdmO{ZXHz[ZMh[WO2aY\lJINie3Cjc3WtNVIhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NH\0VYYzPTF{OECyOS=>
RBE4 NVvuXYFqTnWwY4Tpc44hSXO|YYm= NYDLS5pkOsLizszN NInJT5k{6oDVMkVCpIg> MXnpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUT2OgeIlu\S2mZYDlcoRmdnSueR?= Mn[5NlUyOjhyMkW=
RBE4 NI[4b5hHfW6ldHnvckBCe3OjeR?= NYTJOmwzOsLizszN NEfsTVA{6oDVMkVCpIg> NVTKVGtPcW6mdXPld{BiKGSnbHH5[YQh\GWybHX0bY9vKG:oIITo[UBGWiCFYUKrxsBkd262ZX70JIF1KDcEoHigc4YhcW6ldXLheIlwdiC|aXfubYZq[2GwdHz5 M3;BSFI2OTJ6MEK1
RBE4 NVzXU3RLTnWwY4Tpc44hSXO|YYm= NYDIVIlQOsLizszN MnPFN-KBmzJ2wrDo MkOxbY5lfWOnczDhckBwfmW{bH;h[EBw\iCFYUKrxsBqdiC2aHWgcYl1d2Oqb37kdoliKGmwIITo[UBncXK|dDC2xsBpKG:oIHnuZ5Vj[XSrb36gLJDjiIl:4pEJNE4xODFrIHL1eEBE[TJtwrDs[ZZmdHNiaX6geIhqeyCxcnfhcoVtdGViZHXjdoVie2WmIHHmeIVzKDF{wrDoJI9nKGmwY4XiZZRqd25? MlnONlUyOjhyMkW=
Huh-7  MUPGeY5kfGmxbjDBd5NigQ>? NVrp[WJuOc7:Zz;tUC=> NF;sVZU{6oDVMkVCpIg> NICzWmJqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NFrsSIwzPTB{NkG3OC=>
HepG2  MorNSpVv[3Srb36gRZN{[Xl? MlzHNe69\y:vTB?= NX7KfIVnO+LCk{K0xsBp MVTpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NY\mOpBbOjVyMk[xO|Q>
H838-LKB1 MnfQSpVv[3Srb36gRZN{[Xl? NUfuWVlsOzEEoH7nM41t NF7JeIYyOi9zODDo MU\pcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKEKrUNMg MVqyOVAyOTB6Mh?=
H838-KDLKB1  MVjGeY5kfGmxbjDBd5NigQ>? NUT6ZWxwOzEEoH7nM41t MnzzNVIwOThiaB?= NIjiNJRqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh MUmyOVAyOTB6Mh?=
H838-KDLKB1  M{\KZWZ2dmO2aX;uJGF{e2G7 NIHDRWc{OMLibnevcYw> Mmf6NVIwOThiaB?= MkTwbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicHjvd5Bpd3K7bHH0[YQh\UmIMt8xJEhxcG:|cHjvMYVKTjMQsTm= M2XDOlI2ODFzMEiy
3T3-L1 Mn:5SpVv[3Srb36gRZN{[Xl? NHGxe3M2KM7:Zz;tcC=> MoPZN|AhdWmw NXK5PZVwdWmvaXPzJJRp\SCnZn\lZ5R{KG:oIHnud5VtcW5iYX7kJINifXOnczDyc4J2e3RicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEApW2W{IES3N{kh[W6mIIDoc5NxcG:{eXzheIlwdiCxZjDBV|E3OCBqVHjyJFY1OiCjbnSgV4VzKDV6ODm= M{nPeVI1QDR|OEK3
3T3-L1 MVXGeY5kfGmxbjDBd5NigQ>? MYm1JO69\y:vbB?= M{TrZlMxKG2rbh?= MmDSdoVk[XCrdIXsZZRmeyCrboP1cIlvKGGldHnvckB4cXSqIILld5Bm[3RidH:gdoVofWyjdHnu[{BCc3RiYXP0bZZqfHliYX7kJGFUOTZyIIDoc5NxcG:{eXzheIlwdg>? NU[1W2Z7OjR6NEO4Nlc>
3T3-L1 NGLsNXRHfW6ldHnvckBCe3OjeR?= M1fSdFUh|rypL33s NVXYfm9lOzBibXnu NWTFdXBo[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES= Mk\pNlQ5PDN6Mke=
3T3-L1 MXLGeY5kfGmxbjDBd5NigQ>? NEXIXoI2KM7:Zz;tcC=> NUXHV5I2OcLiaB?= M1PRU4NifXOnczDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPCCkdYSgco91KGmwY4LlZZNmKGmwIHfseYNwe2VidYD0ZYtm NEfOSm8zPDh2M{iyOy=>
3T3-L1 NHXzVI5HfW6ldHnvckBCe3OjeR?= MYi1JO69\y:vbB?= MlO5NeKhcA>? M1jlRYNifXOnczDwbI9{eGixconsZZRqd25ib3[geIhmKE[xeF:xJJRz[W6|Y4LpdJRqd25iZnHjeI9z M1PEcVI1QDR|OEK3
HeLa  NIjMNJVHfW6ldHnvckBCe3OjeR?= M2rNdVUh|rypL33s NX7BR4ZuOyCq M2LOXoNifXOnczDueYNt\WG{IHX4Z4x2e2mxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3JiYX7kJIRm[3KnYYPld{B1emGwc3PybZB1cW:wIH;mJGZwgE9zLYLl[5Vt[XSnZDDn[Y5mew>? MXWyOFg1Ozh{Nx?=
HEK293 M4\iN2Z2dmO2aX;uJGF{e2G7 MlnNOeKh|rypL33s MoDVNVLDqGh? M1zmeYFjd2yrc3jld{BEVUFvaX7keYNm\CCFUlXMSFIhe2WlcnX0bY9v NHrITJQzPDZ6N{SzNS=>
COS-1 NHXpT2NHfW6ldHnvckBCe3OjeR?= MnW1OUDDvWdxbXy= MVSyOEBpyqB? NEKwfVhz\XO2cnnjeJMhdG:lYXzpfoF1cW:wIH;mJG5DKGmwIITo[UBx\XKrboXjcIVieiC{ZXfpc47DqA>? NFy2TVMzPDZ5MUe1NS=>
PRP Mk\WSpVv[3Srb36gRZN{[Xl? MVWxNEDPxE1? M1zYeoFjem:pYYTld{BUTEZvMd8xMY1m\GmjdHXkJGNZS1J5IHX4eIVzdmGuaYrheIlwdsLi Mo\ZNlQ3Pjh5NUC=
RAW264.7 NYnjOGpNSXCxcITvd4l{KEG|c3H5 M3LrXVQh|ryP MkTmOFghcA>? MUXheJRmdnWjdHXzJJRp\SCrbnjpZol1cW:wIH;mJI95NUyGTD3pcoR2[2WmIHHwc5B1d3OrczDhcoQhfGinIH\hZ4ltcXSjdHnvckBw\iClaH;s[ZN1\XKxbDDl[oZtfXhiYomgRYMucEVvMUjBMW5JOg>? NH\VOlAzPDZ|OUCzNi=>
MDMs M{Pxb2Fxd3C2b4Ppd{BCe3OjeR?= NWDsT3IxOTEkgJpOwIcwdWx? MoD3NVIwOTViaB?= NU\KZZVQcW6mdXPld{BieG:ydH;zbZM> MXiyOFU2PjZ7NR?=
PMHs  M4n0eWZ2dmO2aX;uJGF{e2G7 MmL0NVDjiJN{MPMAje69\y:vbB?= M1\0OFI16oDLaB?= NIPJZ4tFVVOR NVniVGRpcW6mdXPl[EBGWiC|dILld5M> MYmyOFQxPzJ2Mh?=
PMHs  MU\BdI9xfG:|aYOgRZN{[Xl? M1\O[VEx6oDVMkFihKnPxGdxbXy= M3L2dVI16oDLaB?= NFjzVIZFVVOR NFruRnFqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? Ml\kNlQ1ODd{NEK=
HEK293/tau MWjGeY5kfGmxbjDBd5NigQ>? NWXYU5F[PSEQvF2= M4Hs[VEwOi92IHi= M1[3OIlv\HWlZYOgS49t\2liZoLh[41mdnSjdHnvcuKh M3PQdFI1OzZ6MEi5
HEK293/tau MV7GeY5kfGmxbjDBd5NigQ>? MVu1JO69VQ>? MYCzJIg> M4TrZolv\HWlZYOgeIF2KGi7cHXydIhwe3Cqb4L5cIF1cW:w NHPPbXEzPDN4OEC4PS=>
ADF NWrUXXhMTnWwY4Tpc44hSXO|YYm= NUn5XWU2OTBizszN M2DCOlE3KGh? NEnH[Y9qdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? MXeyOFIzQDJ|Mh?=
U373  MXzGeY5kfGmxbjDBd5NigQ>? MV:xNEDPxE1? M4r5W|E3KGh? MVrpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> MkPnNlQzOjh{M{K=
RKO-HIPK2i NHK4UYlHfW6ldHnvckBCe3OjeR?= NHTBOlAyOCEQvF2= NXfa[nI6OTZiaB?= MlTEbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NIK1bJIzPDJ{OEKzNi=>
ADF  NUXrUnM3TnWwY4Tpc44hSXO|YYm= MYWxNEDPxE4EoB?= MlqxOkBp NXWxfWlPcW2yYXnyd{B1cGViRFOgZYN1cX[jdHnvci=> MmWyNlQzOjh{M{K=
Huh7 NWr3SYFpTnWwY4Tpc44hSXO|YYm= NFP3Ooc2KM7:Zz;tcC=> M13UdlQhcA>? NULKdHJj[WKxbHnzbIV{KHSqZTDz[YNz\XSrb36gc4YhKGmwdILhZ4VtdHWuYYKgRZBwSg>? MlHQNlQyODBzNEC=
Huh7 M2OzW2Z2dmO2aX;uJGF{e2G7 M3nDblUh|rypL33s Mn;WNUBp Mn7uZ4F2e2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5iQYDvRk1kemW|Y3XueJM> M1nDXlI1OTByMUSw
Huh7 NFXRTFhHfW6ldHnvckBCe3OjeR?= MYm15qCUOTEEoH7nM41t NHO0UZgyOiCq MYfpcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= MXeyOFExODF2MB?=
BAECs NUHkeYx[TnWwY4Tpc44hSXO|YYm= MWS1JO69\y:vbB?= NHXrSJkxNTRiaB?= MluwbY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 NY\3fo1JOjRyOEWyNlU>
Macrophages NHPvOmVHfW6ldHnvckBCe3OjeR?= M2HKSFcyKML3TR?= MnP6OkBp MUXpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi NHz3WJgzPDB|OUe0NC=>
Colo 205 NGn4SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLsT5YxNTVizsznM41N MUG0PEBp NEDrUJZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzJJdqfGhiYX6g[ZN1cW2jdHXkJGlEPTBib3[gglE2KG6pL33M M4XCTVI{QTd|OUm2
Colo 205 M3\LR2Z2dmO2aX;uJGF{e2G7 NHT0cYQxNjBzMj2wMlAzPSEQvHevcWw> NXP1SVU3OTRiZB?= NGPpcI5z\WS3Y3XzJJRp\SClbH;uc4dmdmmlaYT5JI9nKEOxbH:gNlA2KEOVQ4O= NVzJUoQ{OjN7N{O5PVY>
Colo 205 M{nrcGFxd3C2b4Ppd{BCe3OjeR?= NFLLdIIxNjFizsznM41N M1nt[lAuOjRiaB?= NVHkc5N3cW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= MXuyN|k4Ozl7Nh?=
Colo 205 MVvGeY5kfGmxbjDBd5NigQ>? NVTSPYVZOC5yMUWg{txoN22O NIOwPYgzPCCq MYTpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFXSJJN1emW|cz3y[YxifGWmIHflcoV{ MmPGNlM6PzN7OU[=
Colo 205 MXjGeY5kfGmxbjDBd5NigQ>? M2\TNVAvODF3IN88[{9uVA>? MXOyOEBp M2j4[IlvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXB{ MonONlM6PzN7OU[=
IBRS2 MYLGeY5kfGmxbjDBd5NigQ>? NYXEXnJbPSEQvHevcYw> MoruNE42KGh? MnTPSG1UVw>? M2fDXoRqe3K3cITzJJRp\SCHUlfJR{BidmRiR3;s[4nDqA>? MlvINlM6PjN3M{S=
IBRS2 M3LPRmZ2dmO2aX;uJGF{e2G7 NYqyOGM{PSEQvHevcYw> MX2wMlUhcA>? MmnhSG1UVw>? MmDs[Y5p[W6lZYOgSm1FXiCrbn\lZ5Rqd25? MVKyN|k3OzV|NB?=
HeLa M4m0TWZ2dmO2aX;uJGF{e2G7 M3GxflIh|ryP Mn7nNkBpyqB? MVzheJRmdnWjdHXzJJRp\SCWTl[tbY5lfWOnZDDz[YNz\XSrb36gc4YhUUxvMUW= NXXsd3loOjN7NUC4PVI>
HFS  MkHzSpVv[3Srb36gRZN{[Xl? NX\iS2JpOC1zIN88[{9udA>? NEnIW3IzPCCq NELmRWpIVFSSIHX4dJJme3Orb36gdoVi[2inczDhJJBt[XSnYYWgZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODFiwsXnM41t MmrmNlM5QTR4M{O=
HFS  NIL5W4NHfW6ldHnvckBCe3OjeR?= NYWzbFNlOC5yMTFCuYcwdWx? Mkj4NlQhcA>? NXSyfW5{cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGeueXPvd5BpcW6pb3zpdIllKHO7boToZZNmKGenbnXzJIF1KDZiaB?= M2TWZ|I{QDl2NkOz
OVCAR-3 NVPl[nNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrQTYl2OeLCk{G1xsDPxE4EoB?= MoHWNlTDqGh? M1vjPIlv\HWlZYOgZUBtd3O|IH;mJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= Ml7JNlM5OjZ7NkS=
OVCAR-3 M3z6NGZ2dmO2aX;uJGF{e2G7 MXix5qCUOTYEoN88UeKh MnfZNlTDqGh? MXrpcoR2[2W|IH71Z4xm[XJiZHHtZYdm M3TMN|I{QDJ4OU[0
OVCAR-3 MnLORZBweHSxc3nzJGF{e2G7 NHziSokyNTFywrFOwG0> Mn7OOEBp M2X2VYlv\HWlZYOgeIhmKGGldHn2ZZRqd25ib3[gZZBweHSxc3nzMZJmdGG2ZXSgdJJwfGWrboO= NWrKRldSOjN6Mk[5OlQ>
OVCAR-3 NHfGRlBCeG:ydH;zbZMhSXO|YYm= MmXPNVDDqM7:TR?= MXyyOOKhcA>? MXvpcoR2[2W|IHHjeIl3[XSrb36gc4Yh[2G|cHHz[ZM> MmewNlM5OjZ7NkS=
OVCAR-3 NFLUWmFHfW6ldHnvckBCe3OjeR?= M3G0SFHjiJNzMNMg{txO MmrpNlTDqGh? NFf3OmFqdmS3Y3XzJIRqe3K3cITpc44hd2ZidHjlJI1qfG:laH;u[JJq[WxidILhcpNu\W2kcnHu[UBxd3SnboTpZYw> M3fQc|I{QDJ4OU[0
OVCAR-3 MmjwSpVv[3Srb36gRZN{[Xl? MYCx5qCUOTEEoN88US=> NYPyUJdwOjUEoHi= M1PKPYlv\HWlZYOg[o9zdWG2aX;uJI9nKHKnYXP0bZZmKG:6eXflckB{eGWlaXXz M4fUT|I{QDJ4OU[0
OVCAR-3 MUfGeY5kfGmxbjDBd5NigQ>? NEfIPIEy6oDVMUFCpO69VQ>? MkTVNlTDqGh? NVn6R2dtcW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v Mk\yNlM5OjZ7NkS=
MKN45 M3zj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne4TWM2ODxyLkCwNUDPxGdxbXy= NIX5UnUzOzd7M{O0Ni=>
LOVO NV7uTFRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT5TWM2OD1yLkGyJO69\y:vbB?= M1WxTVI{Pzl|M{Sy
A549 M4XHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXPWGZKSzVyPUCuNFQh|rypL33s NHO1VHAzOzd7M{O0Ni=>
MDA-MB-435 NVKxdlBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DrN2lEPTB:MD6wNFEh|rypL33s M1vtT|I{Pzl|M{Sy
HepG2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTOTWM2ODxyLkCwNUDPxGdxbXy= NInGfVMzOzd7M{O0Ni=>
HL-60 NETldHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRDBwMECxJO69\y:vbB?= M1\0S|I{Pzl|M{Sy

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / GRP78 ; 

PubMed: 22859938     


(B) present the dose- and time- dependent effect of ER stress inducer brefeldin A on p53 expression. MCF-7 Cells were exposed to brefeldin A in 10% FBS–supplemented DMEM as time and dose indicated. The cell lysates were analyzed by western blotting with antibodies for p53, GRP78, and α-tubulin. The p53 protein expression level was quantified densitometrically. GRP78 served as an ER stress marker. 

22859938
Immunofluorescence
MTP / GBF1 ; 

PubMed: 26267806     


3T3-L1 cells, plated as above, were treated with brefeldin A (5 μg/ml, 3 hr), fixed and stained for MTP and GBF1. Brefeldin A treatment leads to redistribution of MTP from the juxtanuclear region, similar to what occurs with GBF1. Bars = 10 μm.

ErbB3 / Calnexin ; 

PubMed: 21576364     


293T cells transfected with ErbB3 were treated without (top) or with (bottom) BfA, and confocal immunofluorescence microscopy was used to examine the colocalization of ErbB3 with endogenous calnexin.

FMNL1 / GM130 ; 

PubMed: 21868368     


FMNL1 colocalizes with the cis-Golgi marker GM130 and is dispersed by treatment with brefeldin A (+BFA).

26267806 21576364 21868368
Growth inhibition assay
Cell viability; 

PubMed: 28462831     


Effects of brefeldin A on human prostate cancer cells. LNCaP and PC-3 cells were seeded in cell culture dishes and incubated for 24 h. The cells were then treated with different concentrations of brefeldin A for 72 h. The number of viable cells was determined by the trypan blue exclusion assay. Apoptosis was determined by propidium iodide staining and morphological assessment.

28462831

Protocol

Cell Research:

[5]

- Collapse
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A
Smiles CC1CCCC=CC2CC(CC2C(C=CC(=O)O1)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID